|
|
トップページ >
研究紹介
> 老年病研究チーム >
運動器医学研究 > 主要文献
|
|
 |
|
|
老年病研究チーム
研究テーマ：
運動器医学研究
|
|
|
 |
|
|
1.
|
K.Shigemoto, S. Kubo et al. Myasthenia gravis
experimentally induced with muscle-specific kinase. Annals
of the New York Academy of Science. 2008.
|
|
|
2.
|
K. Shigemoto. Myasthenia gravis induced by
autoantibodies against MuSK. Acta Myologica 2008.
|
|
|
3.
|
K. Ohta, K. Shigemoto, A. Fujinami, N. Maruyama, T.
Konishi, Y. Shimoda, & M. Ohta . Clinical and experimental
features of MuSK antibody positive MG in Japan. Eur J Neurol
2007； 14(9): 1029-1034.
|
|
|
4.
|
T. Konishi, K. Ohta, K. Shigemoto & M. Ohta.
Anti-alkaline phosphatase antibody positive myasthenia
gravis. J Neurol Sci 2007; 263(1-2): 89-93.
|
|
|
5.
|
K. Shigemoto, S. Kubo, N.Maruyama, N. Hato, T.
Yamada, C. Jie, N. Kobayashi, K. Mominoki, Y. Abe, N. Ueda
and S. Matsuda. Induction of myasthenia by immunization
against muscle-specific kinase. J Clin Invest
116(4):p1016-1024, 2006
|
|
|
6.
|
(First two authors equally contributed) K. Ohta, K.
Shigemoto, S. Kubo, N. Maruyama, Y. Abe, N. Ueda, A.
Fujinami and M. Ohta. MuSK Ab described in seropositive MG
sera found to be Ab to alkaline phosphatase. Neurology
65(12):p1988, 2005
|
|
|
7.
|
T. Fujibuchi, Y. Abe, T. Takeuchi, N. Ueda, K.
Shigemoto, H. Yamamoto and K. Kito. Expression and
phosphorylation of TOPK during spermatogenes. Dev Growth
Differ47(9):p637-644, 2005
|
|
|
8.
|
S. Matsuda, N. Kobayashi, T. Terashita, T. Shimokawa, K.
Shigemoto, K. Mominoki, H. Wakisaka, S. Saito, K. Miyawaki,
K. Saito, F. Kushihata, J. Chen, SY. Gao, CY. Li, M. Wang
and T. Fujiwara. Phylogenetic investigation of Dogiel's
pericellular nests and Cajal's initial glomeruli in the
dorsal root ganglion. J Comp Neurol 491(3):p234-245, 2005
|
|
|
9.
|
E. Manktelow, K. Shigemoto, I. Brierley. Characterization
of the frameshift signal of Edr, a mammalian example of
programmed -1 ribosomal frameshifting. Nucleic Acids Res
33(5):p1553-1563, 2005.
|
|
| |
10. |
T. Fujibuchi, Y. Abe, T. Takeuchi, Y. Imai, Y. Kamei,
R. Murase, N. Ueda, K. Shigemoto, H. Yamamoto, K.
Kito.AIP1/WDR1 supports mitotic cell rounding. Biochem
Biophys Res Commun 327(1):p268-275, 2004
|
|
| |
11. |
S. Matsumoto, Y. Abe, T. Fujibuchi, T. Takeuchi, K. Kito,
N. Ueda, K. Shigemoto and K. Gyo. Characterization of a
MAPKK-like protein kinase TOPK. Biochem Biophys Res Commun
325(3):p997-1004, 2004
|
|
| |
12. |
SY. Gao, CY. Li, J. Chen, L. Pan, S. Saito, T.
Terashita, K. Saito, K. Miyawaki, K. Shigemoto, K. Mominoki,
S. Matsuda and N. Kobayashi. Rho-ROCK signal pathway
regulates microtubule-based process formation of cultured
podocytes--inhibition of ROCK promoted process elongation.
Nephron Exp Nephrol 97(2):p49-61, 2004
|
|
| |
13. |
(First two authors equally contributed) K. Ohta, K.
Shigemoto, S. Kubo, N. Maruyama, Y. Abe, N. Ueda and M. Ohta.
MuSK antibodies in AChR Ab-seropositive MG vs AChR
Ab-seronegative MG. Neurology 62(11):p2012-2133, 2004.
|
|
| |
14 |
K. Shigemoto, J. Brennan, E. Walls, CJ. Watson, D. Stott,
PW. Rigby and AD. Reith. Identification and characterization
of a developmentally regulated mammalian gene that utilises
-1 programmed ribosomal frameshifting. Nucleic Acids Res
29(19):p4079-4088, 2001.
|
|
| |
15. |
Abe, S Matsumoto, S Wei, K Nezu, A Miyoshi, K Kito, N Ueda,
K Shigemoto, Y Hitsumoto, J Nikawa and Y Enomoto. Cloning
and characterization of a p53-related protein kinase
expressed in interleukin-2-activated cytotoxic T-cells,
epithelial tumor cell lines, and the testes. J Biol Chem
276(47):p44003-44011, 2001
|
|
| |
16. |
K Obata, T Fukuda, R Morishita, S Abe, S Asakawa, S
Yamaguchi, M Yoshino, K Ihara, K Murayama, K Shigemoto, N
Shimizu and I Kondo. Human biotin-containing subunit of
3-methylcrotonyl-CoA carboxylase gene (MCCA) cDNA sequence,
genomic organization, localization to chromosomal band 3q27,
and expression. Genomics 72(2):p145-152, 2001
|
|
| |
17. |
K Shigemoto, S Kubo, N Maruyama, S Yamada, K Obata, K
Kikuchi and I Kondo. Identification and characterization of
5' extension of mammalian agrin cDNA, the exons and the
promoter sequences. Biochim Biophys Acta 1494(1-2):p170-174,
2000
|
|
| |
|
総説
|
|
| |
18. |
重本和宏、丸山直記. サルコペニア（加齢性筋肉減少症）とそのバイオマーカー. 老年医学.
47(6):p733-735. 2009
|
|
| |
19. |
重本和宏、久保幸穂、丸山直記. 神経筋接合部位の異常と筋力低下.
日本老年医学会雑誌. 46(2):p106-113. 2009
|
|
| |
20. |
重本和宏、太田潔江、小西哲郎、太田光熙. MuSK抗体と重症筋無力症. 神経内科69(4):p336-342.
2008.
|
|
| |
21 |
重本和宏、小西哲朗、丸山直記：免疫性神経疾患Update, 各論 、重症筋無力症 病因・病態Update.
日本臨床 66(6):p1149-1154. 2008.
|
|
| |
22. |
丸山直記、 重本和宏. 神経筋接合部疾患における抗MuSK抗体と病態機序. 臨床神経、47:842-844,
2007.
|
|
| |
23. |
重本和宏. 免疫性神経筋疾患の動物モデル：重症筋無力症. アニテックス、19(6):17-23, 2007
|
|
| |
24. |
重本和宏、久保幸穂、丸山直記：抗MuSK抗体陽性重症筋無力症の病因と病態.基礎老化研究 30(4) p25-30.
2006
|
|
| |
25. |
重本和宏、太田光熙：MuSK(Muscle-specific kinase)とは. 神経内科 65(4):
p325-332, 2006
|
|
| |
26. |
重本和宏、丸山直記：重症筋無力症の新たな病因・病態. BIO Clinica 21(10):p34-38, 2006.
|
|
| |
27. |
重本和宏：神経筋シナプス形成、維持、再生の分子機構の解明（重症筋無力症の分子病態について の新しい展開）. 愛媛医学
25(1):p11-16, 2006.
|
|
| |
28. |
重本和宏、太田光熙、丸山直記：抗MuSK自己抗体陽性重症筋無力症とMuSKの機能について. 神経眼科 22(３)別冊:p304-312, 2005.
|
|
| |
29. |
太田光熙、太田潔江、重本和宏：抗MuSK抗体. 日本臨床 63増刊号(7):p589-591, 2005.
|
|
|
|
|
|
 |
 |
|
2009/07/31
Copyright(C)2009 Tokyo Metropolitan Institute of Gerontology. All rights reserved.
|
